1-吲嗪甲酰胺 | 14759-47-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1-吲嗪甲酰胺
• 英文名称: 1-Carbamoyl-indolizin
• 英文别名: indolizine-1-carboxylic acid amide；Indolizine-1-carboxamide
• CAS: 14759-47-8
• 化学式: C₉H₈N₂O
• mdl: MFCD18810617
• 分子量: 160.175
• InChiKey: DHOQDVKLAJQFSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.5
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE POUVANT ÊTRE EMPLOYÉS DANS DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：MERCK PATENT GMBH

  公开号：WO2016019228A1

  公开（公告）日：2016-02-04

  The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚啉化合物及其药学上可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• [EN] CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] (AZA)INDOLIZINE-CARBOXAMIDES CYCLIQUES, LEUR PRÉPARATION ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2011012538A1

  公开（公告）日：2011-02-03

  The present invention relates to cyclic indolizinecarboxamides and azaindolizinecarboxamides of the formulae Ia and Ib, (Ia) (Ib) wherein R, Ra, R10, R20, R30, R40, Y, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.

  本发明涉及公式Ia和Ib的环式吲哚啉羧酰胺和氮杂吲哚啉羧酰胺，其中R、Ra、R10、R20、R30、R40、Y、n、p和q的含义如索赔中所示，它们是有价值的药用活性化合物。具体来说，它们抑制酶肾素并调节肾素-血管紧张素系统的活性，对于治疗高血压等疾病是有用的。此外，本发明还涉及制备公式Ia和Ib化合物的方法、它们的用途以及包含它们的药物组合物。
• CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：STEINHAGEN Henning

  公开号：US20120232081A1

  公开（公告）日：2012-09-13

  The present invention relates to cyclic indolizinecarboxamides and azaindolizinecarboxamides of the formulae Ia and Ib, wherein R, R a , R 10 , R 20 , R 30 , R 40 , Y, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.

  本发明涉及公式Ia和Ib的环状吲哚啉羧酰胺和氮杂吲哚啉羧酰胺，其中R、Ra、R10、R20、R30、R40、Y、n、p和q在权利要求中所示，它们是有价值的药物活性化合物。具体来说，它们抑制酶酰肽酶并调节肾素-血管紧张素系统的活性，对于治疗高血压等疾病有用。此外，本发明还涉及制备公式Ia和Ib化合物的方法，以及它们的使用和含有它们的制药组合物。
• CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：EP2459557A1

  公开（公告）日：2012-06-06
• NOUVEAUX DERIVES D'INDOLIZINE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
  申请人：Les Laboratoires Servier

  公开号：EP2807159A1

  公开（公告）日：2014-12-03